As of 2025-05-23, the Fair Value of Blueprint Medicines Corp (BPMC) is -12.06 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 100.34 USD, the upside of Blueprint Medicines Corp is -112.02%.
With the market price of 100.34 USD and our fair value calculation, Blueprint Medicines Corp (BPMC) is not a good investment. Investing in BPMC stocks now will result in a potential loss of 112.02%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | 313.90 | -644.10 | -557.50 | -506.98 | -67.09 | -292.35 |
| YoY growth | 190.28% | -305.19% | 13.45% | 9.06% | 86.77% | -1.13% |
| Market Cap (mil) | 6,479.96 |
| P/E | |
| Forward P/E |
| EPS | -2.41 |
| Avg earnings growth rate | -1.13% |
| TTM earnings | -155.73 |